Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
64 巻, 15 号
選択された号の論文の31件中1~31を表示しています
ORIGINAL ARTICLES
  • Masahito Nakano, Machiko Kawaguchi, Dan Nakano, Tomoya Sano, Keisuke A ...
    2025 年64 巻15 号 p. 2263-2269
    発行日: 2025/08/01
    公開日: 2025/08/01
    [早期公開] 公開日: 2025/02/08
    ジャーナル オープンアクセス

    Objective The etiology of liver cancer is changing to metabolic dysfunction-associated steatotic liver disease, and ultrasound elastography is useful for identifying high-risk patients. However, these regional differences remain unclear. We aimed to investigate regional differences in the prevalence of liver cancer and the use of ultrasound elastography in Japan using the National Database of Health Insurance Claims (NDB).

    Methods We used NDB open data from 2020. The standardized claims data ratio (SCR) was used to evaluate regional differences. We investigated medical receipt information for liver cancer, diabetes-related diseases, and elastography in 47 prefectures.

    Results The highest SCR for liver cancer was observed in Kyushu [median 134, IQR (109-139)], followed by Chugoku [113, (110-132)], Kinki [109, (89-126)], and Shikoku [107, (100-121)], highlighting a significant concentration in Western Japan (The mean SCR; 114.9 in Western Japan, 88.5 in Eastern Japan: p<0.0001). A higher SCR has also been observed in the treatment of liver cancer, including hepatic resection and radiofrequency ablation, in Western Japan. Similarly, in Western Japan, higher SCRs have also been observed for diabetes-related diseases, such as glucose intolerance, ischemic cardiovascular disease, angina pectoris, and ischemic cerebrovascular disease. However, the SCR for transient elastography and shear wave elastography is low in many prefectures throughout Japan.

    Conclusion The morbidity of liver cancer and diabetes-related diseases is higher in Western Japan. However, ultrasound elastography is not widely used in Japan. There is an urgent need to promote awareness of ultrasound elastography to screen patients at high risk for liver cancer, particularly in Western Japan.

  • Masahisa Hata, Mitsuyoshi Takahara, Fumiyo Kubo, Yohei Fujita, Ryota T ...
    2025 年64 巻15 号 p. 2270-2275
    発行日: 2025/08/01
    公開日: 2025/08/01
    [早期公開] 公開日: 2024/12/26
    ジャーナル オープンアクセス
    電子付録

    Objective The Glasgow Coma Scale (GCS) is widely used to assess the levels of consciousness. This study examined whether or not the initial GCS score could be a marker of the length of hospital stay (LOS) in patients with thyroid storm.

    Methods We retrospectively analyzed 29 patients with thyroid storm in our hospital between January 2010 and December 2023. Thyroid storm was diagnosed based on the latest diagnostic criteria in Japan. Since 30 days is the upper limit of LOS in the Diagnosis Procedure Combination [DPC]-based reimbursement system, the study population was divided into patients with permissible LOS (<30 days) and those with undesirable LOS (≥30 days). As a supplementary analysis, we examined the correlation of the GCS score and other clinical parameters with LOS using a Spearman's rank correlation analysis.

    Results The GCS score was significantly higher (14.1±2.7 vs. 9.9±4.9 points; p<0.001), and the Sequential Organ Failure Assessment (SOFA) score significantly lower (1.68±2.16 vs. 7.50±7.91 points; p=0.009) in patients with permissible LOS than in those with undesirable LOS, while other clinical parameters were not significantly different between the groups. The area under the receiver operating characteristic curve of the GCS for the permissible vs. undesirable LOS was 0.866. The baseline parameters that were significantly correlated with LOS were the GCS (ρ=-0.665; p<0.001) and SOFA score (ρ=0.670; p<0.001). The subsequent rank partial correlation analysis showed that GCS was still inversely correlated with LOS, independent of SOFA score (ρ=-0.390; p=0.040).

    Conclusion GCS, which can be evaluated more easily and quickly than the SOFA score, is a useful marker of LOS in patients with thyroid storm.

  • Yoko Onodera, Takashi Ishiguro, Ryuji Uozumi, Taisuke Isono, Takashi N ...
    2025 年64 巻15 号 p. 2276-2283
    発行日: 2025/08/01
    公開日: 2025/08/01
    [早期公開] 公開日: 2025/01/03
    ジャーナル オープンアクセス

    Objective Community-acquired pneumonia is an acute infectious disease with potentialy life-threatening consequences. Because invasive mechanical ventilation (IMV) requires the attention of many medical staff, early risk prediction at the time of admission is expected to lead to a predictable course of patient care and the appropriate allocation of medical resources. There are a limited number of reports on predictive factors for IMV, such as SMART-COP. Therefore, further studies are required.

    Methods We retrospectively reviewed cases of patients with community-acquired pneumonia other than coronavirus disease 2019 admitted to our institution from 2002 to 2019. We performed competing risks analysis with the need for IMV from the day after admission as the outcome and used multivariable analysis to identify predictive factors of IMV from admission characteristics.

    Results Among 2,227 patients (mean age 67.3 years, 69.0% male), 39 patients required IMV on or after the day following admission. A multivariable analysis showed that predictive factors of IMV were respiratory rate >30 breaths/min [subdistribution hazard ratio (SHR), 5.53; 95% confidence interval (CI), 2.09 to 14.67; p=0.001], PaO2/FiO2 ratio <250 (SHR, 8.02; 95% CI, 2.78 to 23.13; p<0.001), and Legionella pneumonia (SHR, 4.87; 95% CI, 1.56 to 15.13; p=0.006).

    Conclusion This study revealed that among other factors including mainly vital signs, specific infection by a microorganism itself (Legionella in this study) was a predictive factor for the need of IMV.

  • Yasushi Obase, Susumu Fukahori, Jun Iriki, Yusei Tsukamoto, Yuka Nagae ...
    2025 年64 巻15 号 p. 2284-2289
    発行日: 2025/08/01
    公開日: 2025/08/01
    [早期公開] 公開日: 2025/02/08
    ジャーナル オープンアクセス

    Objective The prevalence rates of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) are 3-11% and 8-16%, respectively, in the general Japanese adult population. Few reports on patients' perceptions of BA, cough variant asthma (CVA), COPD, and asthma and COPD overlap (ACO) are available in Japan, and we aimed to investigate the agreement between the perception and diagnosis of BA and COPD-related diseases.

    Methods The subjects were 229 datasets matched to the sex and age distribution of the Japanese population of 1,000 adult patients who underwent respiratory function tests and screening for each disease at Nagasaki University Hospital between July 2014 and July 2017. The patients' self-perceptions of diagnosed BA, CVA, COPD, emphysema, chronic bronchitis, and ACO were determined.

    Results In total, 229 datasets were included in this study. The prevalence of BA was 10.0% (23 cases, including 2 CVA and 6 ACO cases) and 11.8% (27 cases, including 6 ACO cases). The prevalence of ACO was 2.6% (28.6% of BA and 22.2% of COPD), and that of CVA was 0.9% (8.7% of BA). The perception of COPD-related diseases had a much lower sensitivity than that of asthma-related diseases (0.481 vs. 0.995, p<0.0001). Cohen's kappa for asthma-related disease was 0.976, and that for COPD-related disease was 0.621.

    Conclusion Self-perception of asthma-related disease was adequately high, whereas that of COPD-related disease was low. The prevalence rates of BA, COPD, ACO, and CVA in our study were 10.0%, 11.8%, 2.6%, and 0.9%, respectively. An increase in the perception of COPD may help improve community healthcare for respiratory diseases.

  • Akihiko Mitsutake, Takashi Matsukawa, Rimi Hino, Go Fujino, Yuto Sakai ...
    2025 年64 巻15 号 p. 2290-2294
    発行日: 2025/08/01
    公開日: 2025/08/01
    [早期公開] 公開日: 2025/02/01
    ジャーナル オープンアクセス
    電子付録

    Objective Spastic paraplegia 7 (SPG7) is an autosomal recessive neurodegenerative disorder caused by biallelic pathogenic variants in SPG7. It is predominantly characterized by adult-onset slowly progressive spastic paraparesis. While SPG7 presenting with ataxia with or without spasticity is relatively common in Europe and North America, it is considered rare in Japan. This study aimed to identify SPG7 patients among those with undiagnosed ataxia within the Japanese population.

    Methods We retrospectively selected 351 patients with undiagnosed ataxia, excluding those with secondary and common spinocerebellar ataxia. Whole-exome sequence analysis was conducted, and homozygosity of the identified variants was confirmed using droplet digital polymerase chain reaction (ddPCR).

    Results Among the 351 patients, 2 were diagnosed with SPG7, and homozygosity was confirmed by ddPCR. Both patients carried homozygous pathogenic variants in SPG7: c.1948G>A, p.Asp650Asn, and c.1192C>T, p.Arg398Ter (NM_003119.4). Clinically, both patients presented with progressive ataxia. In addition, Patient 1 exhibited partial ophthalmoplegia and spastic paraparesis, whereas Patient 2 demonstrated cerebellar ataxia without spasticity.

    Conclusion The rarity of SPG7 in Japan may be attributed to variation in the minor allele frequency of the c.1529C>T, p.Ala510Val variant, which is more prevalent in Europe and North America than in other areas.

  • Jumpei Taniguchi, Shotaro Aso, Hiroki Matsui, Kiyohide Fushimi, Hideo ...
    2025 年64 巻15 号 p. 2295-2300
    発行日: 2025/08/01
    公開日: 2025/08/01
    [早期公開] 公開日: 2025/01/03
    ジャーナル オープンアクセス
    電子付録

    Objective Data on the first-line treatment options for patients with Pneumocystis pneumonia (PCP) without human immunodeficiency virus (HIV) infection are limited. Therefore, we evaluated the outcome of pentamidine compared to trimethoprim-sulfamethoxazole (TMP-SMX) in non-HIV patients with PCP.

    Methods We used data from the Japanese Diagnosis Procedure Combination Inpatient Database. We included non-HIV PCP patients who initially received TMP-SMX or pentamidine between July 2010 and March 2022. We categorized eligible patients into TMP-SMX and pentamidine groups and performed a propensity score overlap weighting analysis to compare in-hospital mortality between the groups.

    Results Among 5,870 eligible patients, 5,456 and 414 received TMP-SMX and pentamidine, respectively. Pentamidine treatment was associated with a higher in-hospital mortality than TMP-SMX treatment in the propensity score overlap weighting analysis (23.6% vs. 40.1%; risk difference, 16.5%; 95% confidence interval, 10.8-22.2%; p<0.001).

    Conclusions Based on these findings, pentamidine may not be as effective as TMP-SMX for treating PCP in non-HIV patients.

  • Kazuya Okushin, Kazuhiko Ikeuchi, Makoto Saito, Toshiyuki Kishida, Aki ...
    2025 年64 巻15 号 p. 2301-2306
    発行日: 2025/08/01
    公開日: 2025/08/01
    [早期公開] 公開日: 2025/02/01
    ジャーナル オープンアクセス

    Objective Although the management of coronavirus disease 2019 (COVID-19) has improved, chemoprevention remains a challenge. We recently identified that ursodeoxycholic acid (UDCA) is associated with subclinical infection with severe acute respiratory syndrome coronavirus, implying a reduction in the severity of COVID-19. We analyzed a large medical database to assess the utility of UDCA in the reduction of COVID-19 severity.

    Methods This retrospective observational study was conducted using a large-scale healthcare administrative claims database. We extracted data on patients who were diagnosed with either chronic hepatitis B or C. Among them, patients ≥50 years of age diagnosed with COVID-19 before December 2022 were analyzed. Patients were divided into two groups: those with or without a prescription of UDCA. The primary outcome was the in-hospital mortality rate. A propensity score-matching analysis was performed using logistic regression.

    Results A total of 6,413 patients diagnosed with COVID-19 (UDCA group, n =579; non-UDCA group, n =5,834) were analyzed. The median age was 73.0 (interquartile range, 64.0-81.0) years, and 57.8% of the patients were men. The UDCA group had significantly more complications with liver cirrhosis, hepatocellular carcinoma, type 2 diabetes, and hypertension. The UDCA group had a higher in-hospital mortality rate than the non-UDCA group, even after propensity score matching (7.4% vs. 4.3%, p=0.03), whereas there was no difference in the risks of hospitalization, oxygen therapy, or ventilation.

    Conclusion Although the observed increase in mortality among UDCA users could have been due to unmeasured confounding factors, UDCA did not reduce the severity of COVID-19 in viral hepatitis patients.

CASE REPORTS
PICTURES IN CLINICAL MEDICINE
feedback
Top